Metabolic Enhancement of Ferroptosis and Cuproptosis in Tumors

Study Background and Research Question

Regulated cell death (RCD) pathways such as ferroptosis and the more recently characterized cuproptosis have emerged as promising targets for oncological intervention. Ferroptosis is an iron-dependent, non-apoptotic cell death, while cuproptosis is driven by intracellular copper (Cu) overload, which disrupts mitochondrial protein homeostasis. Both mechanisms bypass common resistance routes in malignant cells and offer avenues for overcoming therapeutic limitations associated with classical apoptosis inducers. Yet, the synchronous activation and potentiation of both ferroptosis and cuproptosis within tumor cells remain poorly explored, especially in the context of metabolic vulnerabilities unique to cancer (source: reference_paper).

Key Innovation from the Reference Study

The pivotal innovation detailed by Zhang et al. is the design and deployment of a metabolic intervention nanosystem—SCu/L—that integrates a glycolysis inhibitor (STF-31) into a copper-tannic acid (Cu-TA) network, encapsulated within liposomes. This composite not only delivers copper directly into tumor cells but simultaneously inhibits glycolysis and NAD+ metabolism, thereby enhancing susceptibility to both ferroptosis and cuproptosis. The approach addresses previous challenges of achieving dual-pathway activation while boosting anti-tumor immunity by remodeling the tumor immune microenvironment (TIME) (source: reference_paper).

Methods and Experimental Design Insights

The experimental framework centers on the synthesis of SCu/L nanoparticles, combining STF-31 (a glycolysis inhibitor) within lipid bilayers and a core Cu-TA network. The system was characterized for physicochemical stability, copper release kinetics, and cellular uptake. Functional assays involved:

• Measurement of intracellular glucose, NAD+, NADPH, and ATP in treated cancer cell lines.
• Assessment of GSH (glutathione) synthesis and Cu-ATPase (copper efflux pump) activity post-treatment.
• Analysis of cell death modalities using pathway-specific markers for cuproptosis and ferroptosis.
• In vivo studies assessing anti-tumor efficacy, immune cell infiltration, and immunogenic cell death (ICD).

The dual-mode action of the SCu/L system was directly compared with controls lacking either the metabolic inhibitor or the copper payload, isolating the contribution of each component to the observed cytotoxic and immunomodulatory effects (source: reference_paper).

Core Findings and Why They Matter

Key results from the study include:

• SCu/L treatment significantly depleted intracellular glucose, NAD+, NADPH, and ATP, reflecting effective metabolic inhibition.
• This deprivation led to impaired GSH synthesis and reduced Cu-ATPase activity, promoting copper accumulation and oxidative stress within mitochondria.
• Concomitant activation of both ferroptosis and cuproptosis was demonstrated via upregulation of lipid peroxidation, loss of mitochondrial membrane potential, and specific aggregation of mitochondrial proteins involved in the TCA cycle.
• In vivo, SCu/L treatment reduced tumor burden and enhanced T-cell-mediated anti-tumor immunity, attributed to immunogenic cell death and remodeling of the TIME (source: reference_paper).

These findings support a paradigm in which metabolic stress—specifically glycolysis and NAD+ metabolism inhibition—synergizes with metal ion-based cytotoxicity to achieve robust and selective tumor cell killing. By orchestrating dual regulated cell death pathways, this approach may overcome resistance mechanisms inherent to single-pathway activation and enhance therapeutic outcomes.

Comparison with Existing Internal Articles

Recent literature, including the internal article "Metabolic Intervention Boosts Ferroptosis and Cuproptosis in Tumors", echoes the central premise of Zhang et al., highlighting the value of metabolic intervention in sensitizing tumors to RCD-based therapies. Similarly, "DeferoxamineB as a Precision Tool for Ferroptosis and Cuproptosis Research" reviews the use of iron chelators like Deferoxamine (DeferoxamineB) to modulate iron-mediated signaling and oxidative stress, supporting dual-pathway research. The current study distinguishes itself by experimentally validating a nanoplatform that merges both metabolic and metal-based strategies, offering a more comprehensive assessment of synergistic mechanisms.

In addition, internal resources such as "Deferoxamine (DeferoxamineB): Iron Chelator & Cancer Research Tool" provide detailed protocol guidance for iron chelation in cancer models, underscoring the translational relevance of chelators and metabolic inhibitors in oncology research.

Limitations and Transferability

Despite its promising results, the nanosystem-based strategy presents several limitations:

• The majority of efficacy and mechanism data are derived from preclinical models; translation to human clinical settings remains to be validated (source: reference_paper).
• Potential off-target effects associated with copper overload and metabolic inhibition require further toxicological assessment.
• The complexity of nanoparticle formulation and delivery may impact scalability and reproducibility across laboratories.

Nonetheless, the integration of metabolic and metal ion stress as dual triggers for RCD represents a versatile framework, with potential applicability to other tumor types or resistant phenotypes, pending further investigation.

Protocol Parameters

• iron chelation assay | 1–10 μM Deferoxamine | cell culture/cancer models | Optimal range for modulating iron-dependent cell death and assessing ferroptosis involvement | product_spec
• apoptosis/autophagy induction assay | ≥5 μM Deferoxamine | cancer cell lines | Triggers antiproliferative, apoptotic, and autophagy pathways for mechanistic study | product_spec
• nanoparticle delivery | 10–50 μg/mL Cu-TA nanoparticles | in vitro and in vivo | Enables direct comparison with metabolic inhibitor-loaded systems | reference_paper
• solution preparation | 6–12.8 mg/mL Deferoxamine in DMSO/water | biochemical assays | Ensures solubility and stability for in vitro application (store at -20°C; avoid long-term solution storage) | product_spec
• workflow suggestion | Optimize for cell line, RCD pathway, and readout | all cancer research models | Adjust concentration and duration according to cell type sensitivity and desired cell death endpoint | workflow_recommendation

Research Support Resources

For laboratories aiming to replicate or extend these regulated cell death studies, Deferoxamine (DeferoxamineB) (SKU BA2746, APExBIO) is a validated iron chelator and apoptosis inducer with robust protocol support for iron metabolism intervention, apoptosis/autophagy induction, and oxidative stress modulation. Researchers can leverage its well-documented solubility and storage characteristics to enhance the precision and reproducibility of their ferroptosis and cuproptosis assays.